AcuCort AB (ACUC) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and a warm welcome to Investor Update, today with Accocort's annual report, which will be presented by CEO Jonas Jönmark. Hi Jonas. Nice to be here, nice to be able to talk about Accocort. Yes, we look forward to that. And as always when we broadcast live, you can interact with the company management, and that makes it easier by writing your questions in the chat field. We will handle those questions at the end of the presentation, but it might be good to get them in as early as possible so we can present them before the broadcast is over. And with that, Jonas, I'll hand it over to you. The stage is yours. Thank you very much. I thought we would talk about the company during 2024, and we will take a deep dive into the last quarter of 2024. But we will also talk about what's coming up. commercialization, the potential of the product and so on. But let's first look at what Accocort does. We have a very smart product called Secmellit, which improves the lives of people with severe allergies. The product is a very smart mouth film. If we look at the fourth quarter of 2024, there has been no turnover during the period as expected. The result after the tax went up to about minus 7.5 million. And we have also started with deductions on our immaterial facilities during the period. In general, there are deductions on research and development that you have to do according to good guidance. The result per share went up to minus 0.09 before the closure and the cash retention at the end of the period went up to approximately 2.7 million SEK. Events during and after the fourth quarter. The first thing we have communicated is that all patients in our study, our phase 4 study, have passed the study and the study results have been processed and we have created a plan now for ho...